01—Abstract
Summary
Summary of the 8-K filed April 1, 2026. Cited figures are marked; the original filing is the authoritative source.
On April 1, 2026, Natera, Inc. (NTRA) filed a Current Report on Form 8-K under Item 5.02 announcing a board change.
Effective March 26, 2026, the Board of Directors increased its size from ten to eleven members and appointed Eric Rubin as a director. Dr. Rubin was named a Class I director with an initial term expiring at the 2028 annual meeting of stockholders, and the Board determined he is independent under Nasdaq listing standards. He was also appointed to the Nominating, Corporate Governance and Compliance Committee.
The filing states Dr. Rubin will receive cash and equity compensation consistent with the company's other non-employee directors, as described in the Amended Compensation Program for Non-Employee Directors previously filed with the SEC. His initial equity award vests as to one-third of the shares on each of March 26, 2027, 2028, and 2029. The company also entered into an indemnification agreement with him, and the filing states there are no family relationships with other directors or executive officers and no related-party transactions requiring disclosure under Item 404(a).
The filing describes a governance change rather than a financial event, and it contains no financial results or operating metrics. The 8-K lists exhibits incorporated by reference to prior SEC filings, including the director compensation program, the Amended and Restated 2015 Equity Incentive Plan, and the form of indemnification agreement, along with the inline XBRL cover page.
02—Key points
Key Highlights
- Board expanded from ten to eleven members, effective March 26, 2026, with Eric Rubin appointed to fill the new seat.
- Dr. Rubin was named a Class I director with an initial term expiring at the 2028 annual meeting of stockholders.
- The Board determined Dr. Rubin is independent under Nasdaq listing standards and appointed him to the Nominating, Corporate Governance and Compliance Committee.
- Dr. Rubin's compensation is consistent with other non-employee directors, with an initial equity award vesting one-third each on March 26, 2027, 2028, and 2029.
- The company entered into an indemnification agreement with Dr. Rubin covering claims related to his service to the company or its subsidiaries.
- The filing states there are no arrangements or understandings with other persons regarding his election, and no family relationships or Item 404(a) related-party interests.
- The 8-K was signed by Michael Brophy, Chief Financial Officer, and dated April 1, 2026.
03—Questions
Frequently Asked Questions
Who was appointed to Natera's board, and when did it take effect?
Eric Rubin was appointed as a member of the Board of Directors, effective March 26, 2026, at the same time the board size was increased from ten to eleven members.
What class and committee is the new director assigned to?
Dr. Rubin was designated a Class I director with an initial term expiring at the 2028 annual meeting of stockholders. The Board appointed him to the Nominating, Corporate Governance and Compliance Committee.
Is the new director considered independent?
Yes. The Board determined that Dr. Rubin qualifies as an independent director under the Securities Act of 1933, as amended, and the listing standards of The Nasdaq Stock Market.
How is Dr. Rubin compensated?
He will receive cash and equity compensation consistent with Natera's other non-employee directors, as described in the Amended Compensation Program for Non-Employee Directors. His initial equity award vests as to one-third of the shares on each of March 26, 2027, 2028, and 2029.
Does the new director have any indemnification protection or related-party interests?
Natera entered into an indemnification agreement with Dr. Rubin providing indemnification and advancement of expenses to the fullest extent permitted by law. The filing states he has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
04—Continue